PS
TXG icon

Principal Securities’s 10x Genomics TXG Stock Holding History

Principal Securities’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-160
Closed -$1.87K – 3357
2025
Q3 		$1.87K Sell
160
-96
-38% -$1.25K ﹤0.01% 3251
2025
Q2 		$2.96K Buy
256
+128
+100% +$1.17K ﹤0.01% 3017
2025
Q1 		$1.84K Hold
128
– – ﹤0.01% 3070
2024
Q4 		$1.84K Buy
128
+48
+60% +$757 ﹤0.01% 3064
2024
Q3 		$1.81K Sell
80
-3
-4% -$62 ﹤0.01% 2984
2024
Q2 		$1.61K Buy
83
+31
+60% +$812 ﹤0.01% 2969
2024
Q1 		$1.95K Sell
52
-4
-7% -$176 ﹤0.01% 2882
2023
Q4 		$3.13K Buy
+56
New +$2.44K ﹤0.01% 2689

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Securities's TXG Position: Q4 2025 in Review

Principal Securities sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 160 shares — an estimated $1.87K sold.

Principal Securities first reported a position in TXG in Q4 2023 and held it in 8 quarters. The position peaked at $3.13K in Q4 2023. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Principal Securities reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 160 10x Genomics shares in Q4 2025, an estimated $1.87K.
  • Principal Securities first reported a position in 10x Genomics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's 10x Genomics position peaked at $3.13K in Q4 2023.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.